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The most significant complication following conven-
tional radiotherapy for residual or recurrent pituitary
tumors is hypopituitarism, which requires life-long hor-
mone replacement therapy.1–3,7,17,24,28 Radiation-induced
hypopituitarism is thought to result from direct damage to
the pituitary gland and secondary damage to the hypothal-
amus. Up to 50% of patients with normal pituitary func-
tions develop hypopituitarism within 5 to 20 years after
undergoing conventional radiotherapy.18,27 The time of
onset is dose dependent, and its incidence increases with
time from exposure.19 Therefore, long-term follow-up stu-
dy in these patients is necessary. 
Radiosurgery has the potential to deliver high doses of
radiation to the target lesion while reducing the dose to the
surrounding normal structures. The proximity of the gland
to the region of treatment, however, may carry the risk of
developing hypopituitarism, even when SRS is applied.
Stereotactic radiosurgery is being used more frequently
in the treatment of pituitary tumors, both functioning and
nonfunctioning, for residual tumor within the cavernous
sinus.10–12,14,15,22,25,26,29 The preliminary data regarding tu-
mor control and normalization of hypersecretory syn-
dromes after SRS appear promising.2,9–17,21,22,25,26,29,30
In cases in which there is cavernous sinus invasion and
residual tumor is expected, the senior author (W.T.C.) has
developed a technique for pituitary transposition (“hypo-
physopexy”) in anticipation of postoperative radiosurgical
treatment. This technique involves transposing the normal
pituitary gland away from the cavernous sinus tumor and
interposing a fat graft between the normal gland and the
tumor in the cavernous sinus. This increases the distance
between the normal pituitary gland and residual tumor to
facilitate SRS treatment of the tumor, thereby reducing the
effective biological dose to the normal pituitary gland.
This reduction decreases the likelihood that hypopituitar-
ism will develop. Although this technique has been de-
scribed in the pituitary literature,4 we detail it here for the
neurosurgical readership and provide illustrative cases.
CLINICAL MATERIAL AND METHODS
Pituitary Transposition
A standard transsphenoidal approach (usually unilateral
endonasal) is initially performed. Via an extended trans-
sphenoidal approach, the osseous removal is then extend-
ed laterally toward the side of the cavernous sinus that in-
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Abbreviations used in this paper: ACTH = adrenocorticotropic
hormone; CA = carotid artery; MR = magnetic resonance; SRS =
stereotactic radiosurgery.
volves tumor.6,20 Maximum tumor resection is performed
while leaving residual tumor in the cavernous sinus. Au-
tologous fat and fascia lata are harvested from the pa-
tient’s thigh in preparation for the pituitary transposition. 
The normal pituitary gland is usually easily dissected
from the adjacent recurrent tumor and displaced laterally
away from the involved cavernous sinus. In addition, a
margin of normal gland is removed from the tumor inter-
face to ensure that none of the lesion is adherent to the
normal gland before transposition. Fat is then interposed
between the gland and the involved cavernous sinus to
maintain the transposition. The closure then proceeds in a
standard fashion, with fascia lata placed over the dural
opening and additional fat graft within the sphenoid sinus
to buttress the fascia.
We normally use autologous fat and fascia as graft ma-
terial to prevent formation of cerebrospinal fluid fistu-
las.5,6,20 The graft in these instances is contiguous with the
standard fat–fascial graft placed in the sella and sphenoid
sinus. Necrosis and shrinkage of the graft are expected in
time and after radiosurgical treatment; this factor must be
considered when undertaking fractionated treatments. If
longer time periods for delivery of fractionated doses are
considered, other more permanent materials, such as bone




History. This 16-year-old woman with acromegaly,
treated at another institution, initially underwent an un-
complicated resection of her pituitary macroadenoma via
a transsphenoidal route. A subtotal resection was per-
formed, with residual tumor remaining in the left cav-
ernous sinus. The patient remained clinically stable for
more than 3 years while attending regular follow-up vis-
its. She then noted some recurrence of the soft-tissue
changes that she had experienced initially. The insulin-
like growth factor–I level had continuously and rapidly
elevated from 151 to 387 ng/ml over a 5-month period,
and her serum growth hormone level had increased to 39
ng/ml. A repeated MR imaging study of the pituitary re-
vealed residual tumor centered in the left cavernous sinus
and in the enlarged sella just medial to it. Because of her
recurrent progressive endocrinopathy and enlarging tu-
mor, treatment was recommended. She refused medical
treatment with a somatostatin analog; therefore, surgical
removal and/or radiosurgical treatment of the remaining
tumor was planned. The patient was young and unmar-
ried; she was adamant about her desire that any planned
treatment not affect her fertility.
Operation. A decision was made to reexplore the sella
and parasellar region. The goals of surgery were maxi-
mum tumor resection and movement of the normal pitu-
itary gland away from the residual tumor in preparation
for radiosurgery. A standard microsurgical sublabial trans-
sphenoidal approach was initially performed, as previous-
ly described.6 Via an extended transsphenoidal route,
additional bone was removed laterally to expose the tumor
in the left lateral sella and cavernous sinus.20 The normal
pituitary gland was easily discernible from the residual
pituitary adenoma. The tumor was dissected from the
gland, and a 2-mm margin of normal lateral gland was
removed to ensure its complete excision from the gland
itself. The tumor was fibrous and difficult to dissect from
the dura and CA. After extirpation of the medial aspect of
the tumor, we decided to leave the remaining tumor in the
cavernous sinus and to treat it radiosurgically to avoid the
risk of CA injury and cavernous cranial neuropathy. A fat
and fascia lata graft was harvested from the lateral thigh.
The pituitary gland was then displaced to the right, and
a fat graft was inserted to hold the gland away from the
residual tumor and cavernous sinus (Fig. 1). Fascia lata
and a fat graft were then placed over the dural opening to
prevent formation of a cerebrospinal fluid fistula. 
Postoperative Course and SRS. The postoperative
course was uneventful, and the patient was discharged to
home on the 3rd postoperative day. On postoperative Day
14 the residual tumor was treated with SRS without com-
plication. Two 10-Gy fractions were delivered 4 weeks
apart by using the Novalis shaped-beam system. Minimul-
tileaf collimators were used to conform the treatment to
the tumor while maintaining the dose to the brainstem and
optic apparatus outside the 60% isodose region (Fig. 1).
Transposition of the pituitary gland laterally with the fat
graft enabled the radiation dose to the gland to be kept
below the 50% isodose. At the time of her second treat-
ment, some necrosis and retraction of the fat graft were
already visible. Both treatments were uneventful. Ten
months after SRS, her growth hormone and insulin-like
growth factor–I levels had decreased to 2.1 ng/ml and 181
ng/ml, respectively. One year postoperatively, normal lev-
els of other adenohypophysial hormones persisted (pro-
lactin, 16 ng/ml) and her usual menstrual periods occurred
approximately every 30 days. External ocular movements
and facial sensation remain intact.
Case 2
History. This 42-year-old woman presented with
Cushing disease secondary to an ACTH-secreting pitu-
itary tumor that extended into the left cavernous sinus
encasing the CA. Her ACTH level preoperatively was 93
pg/ml. A transsphenoidal resection was performed, and
residual tumor, which invaded the left cavernous sinus,
was left in place (Fig. 2). Postoperatively, elevated ACTH
levels of 53 pg/ml persisted, and she suffered from malig-
nant endocrinopathy. She was referred to an endocrinolo-
gist for adjuvant therapy; however, her follow-up status
was suboptimal. A repeated MR imaging study 1 year
later revealed recurrent tumor extending into the suprasel-
lar cistern with radiographically demonstrated stable dis-
ease within the cavernous sinus. 
Operation. Because of her persistent endocrinopathy
(ACTH level 59 pg/ml and elevated 24-hour urine free
cortisol) and recurrent tumor, we decided to reexplore the
sella and parasellar regions, remove all accessible tumor,
and transpose the pituitary gland in preparation for radio-
surgical treatment of the cavernous sinus tumor. An endo-
nasal transsphenoidal approach was used. Bone was re-
moved laterally to expose the tumor in the left lateral sella
and cavernous sinus. A plane was defined between the
normal gland and the tumor. After removing the medial
aspect of the tumor adjacent to the normal gland, a fat
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graft was interposed between the normal gland and the
cavernous sinus tumor. A small piece of fascia lata was
placed adjacent to the dural opening. The sphenoid sinus
was then packed with fat to buttress the graft into position.
A Marlex mesh pledget was fashioned to hold the fat with-
in in the sphenoid sinus. 
Postoperative Course and SRS. The postoperative
course was uneventful, and the patient was discharged
home on the 4th postoperative day. Two weeks later, she
underwent intensity modulation–based radiosurgery for
treatment of the cavernous sinus tumor; a single-fraction
20-Gy dose was prescribed at the 80% isodose line by
using a plan of 22 fixed fields (Fig. 3). This strategy al-
lowed better sparing of her left optic nerve, optic chiasm,
left temporal lobe, and pituitary gland. The pituitary gland
remained outside the 20% isodose line and received ap-
proximately 375 cGy. The patient tolerated the radiation
well without complications. Cranial nerve functions re-
mained intact. At 7 months after SRS, an endocrinological
workup revealed no evidence of hypopituitarism. Her ser-
um cortisol level was 10.1 ✁g/dl. An MR imaging study
demonstrated no evidence of progression of residual tumor.
DISCUSSION
Stereotactic radiosurgery plays an increasing role in pri-
mary and adjuvant treatment of both functioning and non-
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Fig. 1. Case 1. A: Coronal T1-weighted Gd-enhanced MR images demonstrating the relationship of the cavernous
sinus tumor (T), fat graft (F), optic chiasm (OC), and transposed pituitary gland (P). B and C: Isodose curves on coro-
nal image demonstrating doses delivered to surrounding tissues on coronal (B) and axial images (C). Note lateral dis-
placement of the gland by the interposed fat graft on coronal image (B). D: Diagram representing dosimetry target in
relationship to brainstem and optic apparatus with transposed pituitary in green (from Couldwell, et al., 2002, with per-
mission).
Fig. 2. Case 2. Postoperative coronal T1-weighted Gd-enhanced
MR images demonstrating residual pituitary tumor invading the
left cavernous sinus and encasing CA. The pituitary gland is seen
in the right sellar region.
functioning pituitary tumors.8–12,14,15,22,25,26,29,30 This method
of delivering focal radiation is intuitively well suited to
the treatment of localized tumors such as pituitary adeno-
mas. The risk inherent in radiation-based treatments of
pituitary adenomas, perhaps less with radiosurgery, is the
development of hypopituitarism due to exposure of the
adjacent pituitary gland.18,19,27 In cases involving standard
field irradiation treatments (200 cGy/fraction for a total
dose of 5040 cGy) the risk of hypopituitarism is estimat-
ed to be 25% at 5 years and 50% at 10 years after treat-
ment.23 In SRS, a single dose of 10.9 Gy resulted in no
clinical hypopituitarism at a short-term follow-up interval
of 6 months to 2.6 years in patients with acromegaly in
whom surgical therapy had failed.15 No long-term follow-
up studies of pituitary function after radiosurgical treat-
ment of pituitary adenomas have been reported. Our tech-
nique for transposition of the pituitary gland is designed
to increase the distance between the targeted tumor and
the normal pituitary gland to reduce the effective bio-
logical dose to the latter structure. In doing so, the likeli-
hood of inducing hypopituitarism is reduced, which is an
important consideration when treating women of child-
bearing age. 
CONCLUSIONS
We have described a pituitary transposition technique
that may be used in highly selected cases of cavernous
sinus tumor (especially functioning tumors) in patients in
whom postoperative stereotactic radiotherapy or SRS is
planned. This technique is designed to reduce radiation
exposure of the normal gland.
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